NextCure, Inc. (NXTC)

NMS – Real Time Price. Currency in USD

6.78

+0.04 (0.67%)

Market open: Aug 12, 2026, 10:17 AM EDT

6.76

+0.03 (0.48%)

Previous after-hours: Aug 11, 2026, 7:45 PM EDT

10.08.2026

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurrent private investment, and the combined proceeds will support the continued development of Avere's lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Videos

No Data

There is no data to display

Press releases

10.08.2026

NextCure, Inc. (NXTC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NextCure, Inc. (NXTC)

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videos

No Data

Press releases

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videos

No Data

Press releases

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Search stocks

NextCure, Inc. (NXTC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NextCure, Inc. (NXTC)

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videos

No Data

Press releases

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videos

No Data

Press releases

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001